Berlin - Delayed Quote EUR

Bavarian Nordic A/S (BV3.BE)

20.46

-0.42

(-2.01%)

As of 8:34:03 PM GMT+2. Market Open.

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or elevated risk of chikungunya. COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the virus-like particle (VLP)-based, single-dose vaccine, VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for

GlobeNewswire 11 days ago

BVNKF

BVNRY
Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2025 was also adopted.The Remuneration Report for 2024 was not approved. It is noted that this was an indicative vote, and that the decision will not entail consequences on the reported remuneration. The Board of Directors will discuss the decision, and an

GlobeNewswire 19 days ago

BVNKF

BVNRY
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2025 was also adopted.The Remuneration Report for 2024 was not approved. It is noted that this was an indicative vote, and that the decision will not entail consequences on the reported remuneration. The Board of Directors will discuss the decision, and an

GlobeNewswire 19 days ago

BVNKF

BVNRY
FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine reserves.

Pharmaceutical Technology 27 days ago

BAVA.CO
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention of smallpox and mpox disease in adults 18 years of age and older. This approval will provide additional flexibility for stockpiling against a smallpox event or mpox outbreak. The approval follows a standard review with the FDA of a supplemental

GlobeNewswire 27 days ago

BVNKF

BVNRY
Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Wednesday, 9 April 2025, at 4 PM CEST at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda: The Board of Directors' report on the Company's activities in the past year. Presentation of the Annual Report for adoption. A proposal from the Board of Directors regar

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization application and accepted to start the review of the Company’s single-dose chikungunya vaccine, CHIKV VLP vaccine, for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The application was submitted to MHRA in February 2025 under the intern

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic AS (BVNKF) Q4 2024 Earnings Call Highlights: Strong Vaccine Growth and ...

Bavarian Nordic AS (BVNKF) reports robust revenue and EBITDA growth, while navigating manufacturing challenges and market uncertainties.

GuruFocus.com last month

BAVA.CO
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The transactions relate to the award and vesting of restricted stock units (RSUs) und

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic Publishes Annual Report 2024

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2024. The consolidated, audited results were in line with the preliminary results announced on February 3, 2025. The full report is attached as a PDF file and can be found on the Company's website, www.ba

GlobeNewswire last month

BVNKF

BVNRY
EC approves Bavarian Nordic’s chikungunya vaccine marketing

The announcement comes after US FDA approval in February 2025.

Pharmaceutical Technology last month

BAVA.CO
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The virus-like particle (VLP) single-dose vaccine is

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries. COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic’s chikungunya vaccine in low- and middle-income (LMIC) countries. Initially, the companies have entered into a contract manufacturing agreement to

GlobeNewswire 2 months ago

BVNKF

BVNRY
Undiscovered Gems And 2 Other Promising Small Caps With Strong Potential

As global markets continue to navigate a landscape marked by rising inflation and cautious monetary policy adjustments, small-cap stocks have been trailing behind their large-cap counterparts, with the Russell 2000 Index underperforming the S&P 500. However, these conditions can often present unique opportunities for investors seeking potential growth in lesser-known companies that may thrive despite broader economic uncertainties. In this environment, identifying promising small caps...

Simply Wall St. 2 months ago

BVNKF

BVNRY
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Pharmaceutical Technology 2 months ago

BAVA.CO

VLA.PA
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also secured a strong foundation for 2025.Financial guidance for 2025 in line with the Company’s 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025. The preliminary revenue in 2024

GlobeNewswire 2 months ago

BVNKF

BVNRY
EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

Pharmaceutical Technology 2 months ago

BAVA.CO

GLDAF
Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure and meeting the long-term obligations relating to the Company’s share-based incentive programs for the Board of Di

GlobeNewswire 2 months ago

BVNKF

BVNRY
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing authorization. COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marke

GlobeNewswire 2 months ago

BVNKF

BVNRY
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which

GlobeNewswire 2 months ago

BVNKF

BVNRY

Performance Overview

Return	BV3.BE	OMX Copenhagen 25 Index (^OMXC25)
YTD	-19.83%	-9.48%
1-Year	+2.74%	-15.46%
3-Year	+14.72%	-7.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bavarian Nordic A/S (BV3.BE)

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Bavarian Nordic AS (BVNKF) Q4 2024 Earnings Call Highlights: Strong Vaccine Growth and ...

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic Publishes Annual Report 2024

EC approves Bavarian Nordic’s chikungunya vaccine marketing

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Undiscovered Gems And 2 Other Promising Small Caps With Strong Potential

Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Performance Overview